Palliative Care

Psyence Biomedical Ltd (NASDAQ:PBM) recently announced that its wholly-owned subsidiary, Psyence Australia (Pty) received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. The study will examine the use of...

Australia-based MindBio Therapeutics Corp., an ex-subsidiary to Blackhawk Corp. received ethics approval for a Phase 2 clinical trial assessing the effects of LSD microdoses, paired with meaning-centered psychotherapy, on patients with advanced-stage cancer. The randomized, double-blind,...

Psyence Partners with iNGENū for Palliative Care Clinical Trial Life sciences biotech company Psyence Group Inc (OTCQB: PSYGF)’s wholly-owned Australian subsidiary Psyence Australia Pty Ltd. partnered with Contract Research Organization (CRO) iNGENū Pty Ltd to conduct a Phase 2b clinical...

Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal. The agreement allows Psyence the right to commercialize a natural psilocybin compound within the context of palliative care. Psyence CEO Neil Maresky said that the...

A new study is underway to investigate how medical cannabis can help reduce symptoms in children and adolescents with non-cancerous conditions, reported EurekAlert. Palliative Care: Essential for those with serious illnesses.  The pilot study conducted at Australia's...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc. (OTCQB: PSYGF)’s application to assess the efficacy and safety of psilocybin-assisted psychotherapy compared to psychotherapy alone for treating adjustment disorder following an incurable...